Supp Figure 4



Supplemental Figure 4. Peptides unique to Ii$^-$ cells and shared by Ii$^-$ and Ii$^+$ cells activate tumor-reactive PBMC from HLA-DR7$^+$ healthy donors. (**A**) PBMC were primed with Her2 p776 or Ii$^-$ unique peptides #45 (healthy donor PBMC BC100206), #47 (healthy donor PBMC BC100306), or #48 (healthy donor PBMC 100206), and boosted with the cells shown on the X axis**. (B)** PBMC were primed with Her2 p776 or Ii$^-$ and Ii$^+$ shared peptides #42 (healthy donor PBMC BC100306) or #44 (healthy donor PBMC 100206), and boosted as in panel (A)**. (C)** PMBC were primed with peptides 43,46, 48, or HEL 46-61 (HEL) and boosted with the cells indicated on the x axis. Data are from one of three independent experiments.

Supp Figure 5



Supplemental Figure 5. MCF10A cells express HLA-DR upon treatment with IFNγ. MCF10A cells were treated with IFNγ and HLA-DR expression was measured by flow cytometry. MCF10A cells in the left panel were used for the PBMC activation with peptide 43 (Fig 5C, 5D). Cells in the right panel were used for the PBMC activation with peptide 46 (Fig 5C). Data are from two of five independent experiments.

Supp Figure 6



Supplemental Figure 6. Peptides 43, 45 and 46 bind to HLA-DR7 with high affinity. MCF10/DR7/CD80 cells were acid stripped and incubated for 16-20 hrs at 4°C with 0-350 µg/ml of peptide, stained with L243 mAb, and HLA-DR levels determined by flow cytometry. Data are from two of four independent experiments.